Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Real-World Treatment Patterns in Patients with Light Chain (AL) Amyloidosis: Analysis of the Optum US Electronic Health Records and Commercial Claims Database

Angela Dispenzieri, MD, Jeff Zonder, MD, James Hoffman, MD, Sandy W. Wong, MD, Michaela Liedtke, MD, Rafat Abonour, MD, Anita D'Souza, MBBS, Charlene Lee, MSc, Sandhya Nair, PhD MSc, Ravi Potluri, PGDM, Brendan M. Weiss, MD, Jessica Vermeulen, MD PhD, Annette Lam, MSc, Maneesha Mehra, MPH

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140405

Published: 2020

Journal Articles

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Ying Sheng, Chiung-Yu Huang, PhD, Sophia Byslma, BS, Kelsey Natsuhara, MD, Dhruba Biswas, Mimi Lo, PharmD, BCPS, BCOP, Weiyun Z. Ai, Lawrence D Kaplan, MD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Nina Shah, MD, Charalambos Andreadis, MD MSCE, Sandy W. Wong, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-138940

Published: 2020

Journal Articles

Patterns of Tocilizumab Use Among Myeloma Patients Receiving Bcma-Directed Therapies: Effect on Day 30 Outcomes

Jeffrey Marsal, BS, Rahul Banerjee, MD, Chiung-Yu Huang, PhD, Mimi Lo, PharmD, BCPS, BCOP, Vanessa E Kennedy, MD, Shagun Arora, MD, Jeffrey L. Wolf, MD, Thomas Martin, III, MD, Sandy W. Wong, MD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-138618

Published: 2020

Journal Articles

Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex

Swetha Kambhampati, MD, Sandy W. Wong, MD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Priya Choudhry, PhD, William Karlon, MD PhD, Arun P. Wiita, MD PhD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-138869

Published: 2020

Journal Articles

Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)

Julia Piasecki, BA, Todd Devries, PhD, Aditya Radhakrishnan, PhD, Yan Li, PhD, Mark Heipel, BS, Brian A. Fox, PhD, Valeria Beckett, MS, Mariana Cota Stirner, MD PhD, Kristin Conte, MPH, Thomas Doerr, MSc, Sham Mailankody, MBBS, Sandy W. Wong, MD, Philip L. McCarthy, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-137786

Published: 2020

Journal Articles

Macrophage Activation Syndrome-like Manifestations (MAS-L) Following BCMA-Directed CAR T-Cells in Multiple Myeloma

Vanessa E Kennedy, MD, Christopher Wong, Chiung-Yu Huang, PhD, Jeffrey L. Wolf, MD, Thomas Martin, MD, Nina Shah, MD, Sandy W. Wong, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-142612

Published: 2020

Journal Articles

Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

Blood (2020) 136 (Supplement 1): 48–50.

https://doi.org/10.1182/blood-2020-137582

Published: 2020

Journal Articles

Incidence, Management and Outcomes of Arterial and Venous Thromboembolism after Chimeric Antigen Receptor Modified T Cells for B-Cell Lymphoma and Multiple Myeloma

Anna L. Parks, MD, Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Charalambos Andreadis, MD, Lissa Gray, MSN, Sandy W. Wong, MD, Nina Shah, MD, Margaret C. Fang, MD MPH

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-136782

Published: 2020

Journal Articles

Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma

Joaquin Martinez Lopez, Rafael Alonso Fernández, Sandy W. Wong, MD, Rafael Rios, MD PhD, Nina Shah, MD, Maria Teresa Cedena Romero, MD PhD, Yanira Ruiz-Heredia, Jose M. Sanchez, MD, Santiago Barrio Garcia, PhD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-140352

Published: 2020

Journal Articles

Outcomes of Plasma Cell Leukemia Patients in the Era of Next-Generation Novel Agents: A Single-Center Retrospective Cohort Study

Alex Ge, Chiung-Yu Huang, PhD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Nina Shah, MD, Sandy W. Wong, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141525

Published: 2020

Journal Articles

Digital Life Coaching for Myeloma Patients Undergoing Transplantation

Rahul Banerjee, MD, Ann Lazar, PhD MS, Lisa Dunn, RN, Jennifer Knoche, RN, Kelly Jean Brassil, PhD MA, MSN, RN, Dhiren Patel, PharmD, Lindsey Jackson, MPH, CPH, Mimi Lo, PharmD, BCPS, BCOP, Anand Dhruva, MD, Shagun Arora, MD, Sandy W. Wong, MD, Jeffrey L. Wolf, MD, Thomas Martin, III, MD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-134163

Published: 2020

Journal Articles

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Blood (2020) 136 (Supplement 1): 37–40.

https://doi.org/10.1182/blood-2020-139438

Published: 2020

Journal Articles

Germline Variation Predicts Treatment Response in Multiple Myeloma

Kyle Roter, BSc, Donglei Hu, PhD, Alyssa Clay-Gilmour, PhD, Scott Huntsman, Nina D. Shah, MD, Sandy W. Wong, MD, Thomas G. Martin, III, MD, Jeffrey Lee Wolf, MD, Moritz Binder, MDMPH, Shaji K. Kumar, MD, S. Vincent Rajkumar, MD, Susan L. Slager, PhD, Celine M. Vachon, PhD, Elad Ziv, MD

Blood (2019) 134 (Supplement_1): 4397.

https://doi.org/10.1182/blood-2019-129344

Published: 2019

Journal Articles

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Ian Ferguson, BA, Yu-Hsiu T. Lin, BA, Sami Tuomivaara, PhD, Jeffrey L. Wolf, MD, Thomas G. Martin, III, MD, Sandy W. Wong, MD, Nina D. Shah, MD, Christoph Driessen, MD, Brian G. Van Ness, PhD, Arun P. Wiita, MD PhD

Blood (2019) 134 (Supplement_1): 1803.

https://doi.org/10.1182/blood-2019-131681

Published: 2019

Journal Articles

Retrospective Analysis of Modified Hyper-CVAD Therapy Combined with Proteasome Inhibition for Patients with Multiple Myeloma and Renal Insufficiency or Renal Failure

Derek Galligan, MD, Rupa Narayan, MD, Sarah Kim, PharmD, Ann Lazar, PhD MS, Marisela Tan, PharmD, Richard Fong, PharmD, Mimi Lo, PharmD, Nina Shah, MD, Shagun Arora, MD, Sandy W. Wong, MD, Thomas G. Martin, III, MD, Jeffrey Lee Wolf, MD

Blood (2018) 132 (Supplement 1): 3236.

https://doi.org/10.1182/blood-2018-99-111625

Published: 2018

Journal Articles

Rain (Renal AL Amyloid Involvement And NEOD001): A Multicenter, Randomized, Phase 2b Study of NEOD001 in Previously Treated Subjects With Systemic AL Amyloidosis and Persistent Renal Involvement

Cindy Varga, MD BSc, Angela Dispenzieri, MD, Morie A. Gertz, MD, Stacey A Goodman, MD MS, Kristen Hsu, Leslie Inker, MD, Heather Landau, MD, Nelson Leung, MD, Joseph R. Mikhael, MD, Taimur Sher, MD, Brendan M Weiss, MD, Sandy W. Wong, MD, Jeffrey A Zonder, MD, Raymond L. Comenzo, MD

Blood (2017) 130 (Supplement 1): 5437.

https://doi.org/10.1182/blood.V130.Suppl_1.5437.5437

Published: 2017

Journal Articles

Risk-Adapted Melphalan and Stem Cell Transplantation after Suboptimal Responses to Bortezomib-Based Initial Therapy in Patients with Systemic Light-Chain Amyloidosis (AL)

Sandy W. Wong, MD, Denise Larivee, RN, Melissa Warner, BS, Kellie Sprague, MD, Terry Fogaren, RN, BSN, Raymond L. Comenzo, MD

Blood (2016) 128 (22): 5831.

https://doi.org/10.1182/blood.V128.22.5831.5831

Published: 2016

Journal Articles

Impact of Cardiac Stage and Hematologic Response on AL Amyloidosis Patients with Renal Involvement

Sandy W. Wong, MD, Denis Toskic, BS, Melissa Warner, BS, Alejandro Moreno-koehler, MPH, Daniel Fein, MD, Terry Fogaren, RN, BSN, Lisa Lee, MD, Colin Oliver, PhD MBA, Spencer D. Guthrie, MBA, Raymond L. Comenzo, MD

Blood (2016) 128 (22): 2136.

https://doi.org/10.1182/blood.V128.22.2136.2136

Published: 2016

Journal Articles

The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis

Sandy W. Wong, MD, Giovanni Palladini, MD PhD, Ute Hegenbart, MD, Heather Landau, MD, Melissa Warner, BS, Arnaud Jaccard, MD PhD, Herve Avet-Loiseau, Timon Hansen, MD, Joan Bladé, MD, María Teresa Cibeira, MD, Efstathios Kastritis, MD, Stefan Schönland, MD, Raymond L. Comenzo, MD

Blood (2015) 126 (23): 3049.

https://doi.org/10.1182/blood.V126.23.3049.3049

Published: 2015

Journal Articles

Improvements in Patient Outcomes with Autologous Stem Cell Transplantation for Multiple Myeloma over 25 Years at a Single Center

Sandy W. Wong, MD, Melissa Warner, BS, Alejandro Moreno-Koehler, MPH, Athena Kritharis, MD, Michael E Coyle, MD, Deborah Black, RN, BSN, Valerie Relias, PharmD, BCOP, Terry Fogaren, RN, BSN, Nancy Cody Lyons, NP, Francois Toka, NP-C, Denise Larivee, RN, Hedy Smith, MD PhD, Andrew M. Evens, DO, MSc, Grace Kao, MD, Kellie Sprague, MD, Andreas K. Klein, MD, Kenneth B. Miller, MD, Raymond L. Comenzo, MD

Blood (2015) 126 (23): 5496.

https://doi.org/10.1182/blood.V126.23.5496.5496

Published: 2015

NARROW

Real-World Treatment Patterns in Patients with Light Chain (AL) Amyloidosis: Analysis of the Optum US Electronic Health Records and Commercial Claims Database

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Patterns of Tocilizumab Use Among Myeloma Patients Receiving Bcma-Directed Therapies: Effect on Day 30 Outcomes

Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex

Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)

Macrophage Activation Syndrome-like Manifestations (MAS-L) Following BCMA-Directed CAR T-Cells in Multiple Myeloma

Incidence, Management and Outcomes of Arterial and Venous Thromboembolism after Chimeric Antigen Receptor Modified T Cells for B-Cell Lymphoma and Multiple Myeloma

Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma

Outcomes of Plasma Cell Leukemia Patients in the Era of Next-Generation Novel Agents: A Single-Center Retrospective Cohort Study

Digital Life Coaching for Myeloma Patients Undergoing Transplantation

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Germline Variation Predicts Treatment Response in Multiple Myeloma

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Retrospective Analysis of Modified Hyper-CVAD Therapy Combined with Proteasome Inhibition for Patients with Multiple Myeloma and Renal Insufficiency or Renal Failure

Rain (Renal AL Amyloid Involvement And NEOD001): A Multicenter, Randomized, Phase 2b Study of NEOD001 in Previously Treated Subjects With Systemic AL Amyloidosis and Persistent Renal Involvement

Risk-Adapted Melphalan and Stem Cell Transplantation after Suboptimal Responses to Bortezomib-Based Initial Therapy in Patients with Systemic Light-Chain Amyloidosis (AL)

Impact of Cardiac Stage and Hematologic Response on AL Amyloidosis Patients with Renal Involvement

The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis

Improvements in Patient Outcomes with Autologous Stem Cell Transplantation for Multiple Myeloma over 25 Years at a Single Center

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only